ArticleKidney international supplements2013
Slowing progression of chronic kidney disease.
Article in Kidney international supplements, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Key determinants of self-management in patients with non-dialysis-dependent chronic kidney disease: a systematic review.Public health reviews · 2026Pooled it
- Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Trial
- Trial
- Trends in mortality with chronic obstructive pulmonary disease as the underlying cause and chronic kidney disease as a contributing cause among US adults, 1999-2020: a CDC WONDER analysis.BMC pulmonary medicine · 2026Observational
- Predicting the Future Burden of Renal Replacement Therapy in Türkiye Using National Registry Data and Comparative Modeling Approaches.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026Article
- Efficacy and safety of finerenone in chronic kidney disease stages 3-4 in diabetic and non-diabetic patients with an eGFR 20-60 mL/min: a prospective cohort study.Frontiers in nephrology · 2026Article
- Impact of arteriovenous fistula formation on trajectory of kidney function decline: a target trial emulation.Clinical kidney journal · 2024Article
- CareKnowDo-A Multichannel Digital and Telephone Support Program for People With Chronic Kidney Disease: Feasibility Randomized Controlled Trial.JMIR formative research · 2023Article
- Chronic kidney disease is more prevalent among women but more men than women are under nephrological care : Analysis from six outpatient clinics in Austria 2019.Wiener klinische Wochenschrift · 2023Article
- Mitochondrial CPT1A: Insights into structure, function, and basis for drug development.Frontiers in pharmacology · 2023Review
- Improvement in the Blood Urea Nitrogen and Serum Creatinine Using New Cultivation ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Vascular Calcification as a Novel Risk Factor for Kidney Function Deterioration in the Nonelderly.Journal of the American Heart Association · 2021Article
- Transforming growth factor-beta and liver injury in an arginine vasopressin-induced pregnant rat model.Clinical and experimental reproductive medicine · 2021Article
- Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis.The Journal of clinical investigation · 2021Article
- Designing for the Co-Use of Consumer Health Technology in Self-Management of Adolescent Overweight and Obesity: Mixed Methods Qualitative Study.JMIR mHealth and uHealth · 2020Article
- Association between Food Label Unawareness and Loss of Renal Function in Diabetes: A Cross-Sectional Study in South Korea.International journal of environmental research and public health · 2020Article
- County-level air quality and the prevalence of diagnosed chronic kidney disease in the US Medicare population.PloS one · 2018Article
- Renin-angiotensin II-aldosterone system blockers and time to renal replacement therapy in children with CKD.Pediatric nephrology (Berlin, Germany) · 2017Observational
- TGF-β signaling in the kidney: profibrotic and protective effects.American journal of physiology. Renal physiology · 2016Review
- Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early identification of chronic kidney disease (CKD) provides an opportunity to implement therapies to improve kidney function and slow progression. The goal of this article is to review established and developing clinical therapies directed at slowing progression. The importance of controlling blood pressure will be discussed along with the target blood pressure that should be achieved in CKD patients. Therapy directed at inhibiting the renin-angiotensin-aldosterone system remains the mainstay of treatment with single-agent inhibition of this system being as good as dual blockade with fewer adverse effects. Other therapies that may be used include correction of metabolic acidosis, dietary protein restriction, and new models for delivering care to patients with CKD. Emerging therapies targeting endothelin, uric acid, kidney fibrosis, and oxidant stress hold promise for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.